

From: "Don Spongberg" <[REDACTED]>

To: "[REDACTED]" <[REDACTED]>

Subject: Vesselon Recent White Paper - The Need and Future Market for Noninvasive Early Stroke Therapeutics in the Urgent Setting

Date: Fri, 16 Jan 2015 14:46:32 +0000

If you have trouble viewing this email, [read the online version](#).



Vesselon Recent White Paper

Dear Jeffrey,

I am happy to share Vesselon's recent White Paper with you.

This white paper is about one of our most recent ventures – Vesselon, which is in the process of developing the world's first treatment device for stroke, the 2nd leading cause of death worldwide.

The purposes of the white paper are to provide an overview of the huge limitation of the current "gold standard" and only FDA-approved stroke drug – tPA, explain how Vesselon's solution could solve the real problem, and explain why the target market of Vesselon's stroke treatment device could be as large as \$4 billion.

[Click here](#) to access the White Paper.

Please call to learn more about how you can help Vesselon reach its goals.

Sincerely,

Don Spongberg

Senior Managing Director

Spencer Trask Ventures, Inc.

Member FINRA & SIPC

1700 E Putnam Ave, Old Greenwich, CT 06870

Phone: [REDACTED]
[REDACTED]

**Download
White Paper Now!**



**The Need and Future Market for
Noninvasive Early Stroke
Therapeutics in the Urgent Setting**



INVESTMENTS IN THIS OFFERING SHALL BE RESTRICTED SOLELY TO ACCREDITED INVESTORS THAT HAVE BEEN VERIFIED BY THE COMPANY AND THE PLACEMENT AGENT IN ACCORDANCE WITH RULE 506(c) UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

FOR INFORMATION PURPOSES ONLY. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy any security in Vesselon, Inc. (the "Company"). An offer can be made only pursuant to the Confidential Private Placement Memorandum of the Company, and only in states in which the offering of the securities is registered, or is exempt from registration and only by broker-dealers authorized to do so.

To the extent an inconsistency exists between this material and the Company's Confidential Private Placement Memorandum, dated July 30, 2014, as the same may be amended, supplemented or otherwise modified from time to time (the "PPM"), the disclosure in the PPM shall control.

This email message is for the sole use of the intended recipient and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. Any views expressed in this message are those of the individual sender, except where the sender specifically states them to be the views of Spencer Trask Ventures, Inc.

[Click here](#) to manage your email subscriptions. [View the online version](#) of this email.

Spencer Trask Ventures, Inc.

Member FINRA & SIPC

1140 Avenue of the Americas, 9th Floor, New York, NY 10036
1700 East Putnam Avenue, Suite 302, Old Greenwich, CT 06870
800-622-7078